The National Institute for Health and Clinical Excellence (NICE) has opened its public consultation on the use of belimumab (Benlysta) for treating systemic lupus erythematosus. In the draft guidance, NICE is provisionally unable to recommend belimumab for treating adult patients with active autoantibody-positive systemic lupus erythematosus, where patients have a high degree of disease activity despite the individual receiving standard therapy, in line with the drug’s marketing authorisation.
You can register your comments directly on the NICE website until the 21st October 2011.
If you like this, please share:
Find out how we help support people living with lupus.
Enter your email address and receive notifications of new posts by email.